In Brief
Refine Search
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Biotechnology
US pharma major Eli Lilly and Egyptian firm EVA Pharma have entered into an agreement to expand access to Olumiant (baricitinib) to an estimated 20,000 people in 49 low- to middle-income countries in Africa by 2030. 6 September 2024
Biotechnology
US biotech company Novavax, a specialist in protein-based vaccines, has detailed its latest plans for job cuts to save funds for the cash-strapped company. 1 February 2024
Biotechnology
Adaptimmune Therapeutics saw its shares leap almost 10% by close of trading Wednesday and a further 5.2% to $1.01 in after-hours trading as it announced a regulator development for its cell therapy. 1 February 2024
Pharmaceutical
China-based Innovent Biologics recently made a significant breakthrough in obesity treatment with mazdutide, showcasing promising Phase III (GLORY-1) results. 1 February 2024
Biotechnology
Californian firm Synthekine, a specialist in engineered cytokine therapeutics, has agreed a global collaboration with Sanofi. 1 February 2024
Biotechnology
The UK’s health technology assessor the National Instituted for Health and Care excellence (NICE) has recommended Tepkinly (epcoritamab), from US pharma major AbbVie, as a treatment option for eligible adults with an aggressive and fast-growing blood cancer. 1 February 2024
Biosimilars
The Indian market for adalimumab is poised for significant growth. 1 February 2024
Biosimilars
The US Food and Drug Administration (FDA) yesterday released the Revised Biosimilar User Fee Amendment (BsUFA) Research Roadmap to provide updated information about the biosimilar regulatory science research pilot program research priorities. 1 February 2024
Pharmaceutical
All ongoing clinical trials in the European Union (EU) must be transitioned to the Clinical Trials Information System (CTIS) by January 31, 2025. 31 January 2024
Biotechnology
UK health assessor the National Institute for Health and Care Excellence (NICE) has issued its Final Guidance in England and Wales recommending the use of Zynlonta (loncastuximab tesirine), from Swedish Orphan Biovitrum. 31 January 2024
Biosimilars
Sandoz, the recent generic and biosimilar medicines spin out from Novartis , today announced the launch of Tyruko (natalizumab) in Germany from February 1. 31 January 2024
article
Danish diabetes care giant Novo Nordisk this morning released financial results for full year 2023, showing that sales increased by 31% in kroner and by 36% at constant exchange rates to 232.3 billion kroner ($33.9 billion) in 2023 31 January 2024
Pharmaceutical
British drugmaker GSK has exceeded expectations in the fourth quarter, with chief executive Dame Emma Walmsley presenting an upbeat view of the company’s trajectory. 31 January 2024
Biotechnology
Weaker-than-expected revenues from prostate cancer med Pluvicto (lutetium vipivotide tetraxetan) held back Swiss cancer giant Novartis in its latest financial results statement. 31 January 2024
Biotechnology
Chicago, USA-based biotech COUR Pharmaceuticals has raised $105 million in a series A financing round, co-led by Lumira Ventures and Alpha Wave Ventures. 31 January 2024
Biotechnology
US gene therapy company Avrobio and privately-held biotech Tectonic Therapeutic today announced that the companies have entered into a definitive merger agreement to combine in an all-stock transaction. 31 January 2024
Biotechnology
US cell and gene therapy biotech 2seventy bio saw its share close up almost 15% at $4.01 yesterday, after it announced that it is transforming the company. 31 January 2024
Pharmaceutical
Private company Defender Pharmaceuticals has had its submission for a new motion sickness treatment rejected by the US Food and Drug Administration. 31 January 2024
Biotechnology
UK pharma major GSK today announced that its Omjjara (momelotinib) has now been granted Marketing Authorization (MA) in Great Britain by the Medicines and Healthcare products Regulatory Agency (MHRA), following approval by the European Commission earlier this week. 31 January 2024
Biotechnology
Japan has recently approved Dutch immunology specialist argenx’ (Euronext: ARGX) Vyvdura (efgartigimod alfa and hyaluronidase-qvfc) subcutaneous (SC) injection for the treatment of adult patients with generalized myasthenia gravis (gMG), who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs). 31 January 2024
Biotechnology
A division of Indian generics drugmaker Glenmark Pharmaceuticals has agreed terms for a licensing deal with Chinese firms Alphamab Biopharmaceuticals and 3D Medicines. 30 January 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze